TERN (STOCKS)
Terns Pharmaceuticals, Inc. Common Stock
$39.036900
+0.846900 (+2.22%)
Prev close: $38.190000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Amy L. Burroughs
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,153.19M
- Employees
- 59
- P/E (TTM)
- -37.01
- P/B (TTM)
- 11.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.27 | $-0.30 | +0.0323 | +10.68% |
|
Jun 2025 (Q2)
|
$-0.26 | $-0.30 | +0.0358 | +12.10% |
|
Mar 2025 (Q1)
|
$-0.26 | $-0.29 | +0.0256 | +8.96% |
|
Dec 2024 (Q4)
|
$-0.24 | $-0.32 | +0.0761 | +24.07% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $108.48M |
| Nonoperating Income/Loss | $14.28M |
| Operating Income/Loss | -$108.48M |
| Income/Loss From Continuing Operations After Tax | -$94.44M |
| Income/Loss From Continuing Operations Before Tax | -$94.20M |
| Income Tax Expense/Benefit | $238.00K |
| Net Income/Loss | -$94.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$94.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$94.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.02 |
| Diluted Earnings Per Share | -$1.02 |
| Basic Average Shares | 95,523,962 |
| Diluted Average Shares | 95,523,962 |
| Assets | $301.65M |
| Current Assets | $300.30M |
| Noncurrent Assets | $1.36M |
| Fixed Assets | $59.00K |
| Other Non-current Assets | $1.30M |
| Liabilities | $17.59M |
| Current Liabilities | $15.39M |
| Accounts Payable | $2.95M |
| Wages | $4.24M |
| Other Current Liabilities | $8.20M |
| Noncurrent Liabilities | $2.20M |
| Equity | $284.07M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $284.07M |
| Liabilities And Equity | $301.65M |
| Net Cash Flow From Operating Activities | -$77.68M |
| Net Cash Flow From Operating Activities, Continuing | -$77.68M |
| Net Cash Flow From Investing Activities | -$42.39M |
| Net Cash Flow From Investing Activities, Continuing | -$42.39M |
| Net Cash Flow From Financing Activities | $696.00K |
| Net Cash Flow From Financing Activities, Continuing | $696.00K |
| Exchange Gains/Losses | -$68.00K |
| Net Cash Flow | -$119.44M |
| Net Cash Flow, Continuing | -$119.37M |
| Comprehensive Income/Loss | -$94.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$94.49M |
| Other Comprehensive Income/Loss | -$308.00K |